A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States

被引：0
|
作者：
Watson, Lucy [1 ]
Harrison, Owen [1 ]
Cockrum, Paul [2 ]
Veazey, Kylee [2 ]
Gaugris, Sabine [1 ]
Kim, George [3 ]
机构：
[1] FIECON, St Albans, England
[2] Ipsen, Cambridge, MA USA
[3] Mayo Clin Florida, Div Hematol & Oncol, Jacksonville, FL USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
IBCL; tazemetostat; relapsed/refractory follicular lymphoma; R/R FL; budget impact; cost saving;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-461
引用
收藏
页码：S498 / S499
页数：2
相关论文
共 50 条
  • [31] Matching-Adjusted Indirect Comparison (MAIC) of efficacy and safety for tisagenlecleucel and mosunetuzumab in patients (pts) with Relapsed/Refractory (r/r) Follicular Lymphoma (FL)
    Dreyling, M.
    Fowler, N.
    Schuster, S.
    Yang, H.
    Xiang, C.
    Ramos, R.
    Maier, H.
    Jousseaume, E.
    Thieblemont, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 50 - 51
  • [32] Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
    Kim, Tae Min
    Taszner, Michal
    Cho, Seok-Goo
    Novelli, Silvana
    Le Gouill, Steven
    Poon, Michelle Limei
    Villasboas, Jose C.
    Champion, Rebecca
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu Alonso
    Jagadeesh, Deepa
    Merli, Michele
    Tucker, David
    Cai, Jingxian
    De Oliveira, Carolina Leite
    Zhu, Min
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Luminari, Stefano
    BLOOD, 2022, 140 : 2280 - 2282
  • [33] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat
    Lihou, Christine F.
    Cheng, Lulu
    Scholz, Christian W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
  • [34] Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
    Vitolo, Umberto
    Merli, Michele
    Norasetthada, Lalita
    Wassenaar, Timothy Robert
    Martin, Eva Maria Donato
    Bobillo, Sabela
    Shen, Biyi
    Flink, Dina M.
    Zhu, Min
    Chandrasekharan, Soujanya
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Cordoba, Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] The PI3K Inhibitor ME-401 ± Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    Pagel, John
    Zelenetz, Andrew
    Reddy, Nishitha
    Jagadeesh, Deepa
    Stathis, Anastasios
    Salman, Huda
    Soumerai, Jacob
    Kenkre, Vaishalee
    Asch, Adam
    Jhangiani, Haresh
    Llorin-Sangalang, Judith
    Wood, Jamie
    Gorbatchevsky, Igor
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S32 - S32
  • [36] Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)
    Soumerai, Jacob D.
    Diefenbach, Catherine S.
    Samaniego, Felipe
    Kumar, Abhijeet
    Tsai, Michaela L.
    Asch, Adam S.
    Jagadeesh, Deepa
    Kenkre, Vaishalee P.
    Lossos, Izidore S.
    Salman, Huda
    Awan, Farrukh T.
    Miao, Lu
    Ghalie, Richard G.
    Zelenetz, Andrew D.
    BLOOD, 2022, 140
  • [37] COST-EFFECTIVENESS OF ZANUBRUTINIB plus OBINUTUZUMAB FOR TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN THE UNITED STATES
    Gaballa, S.
    Xue, M.
    Swami, S.
    Bhardwaj, A.
    Sharma, R.
    Mohseninejad, L.
    Massoudi, M.
    Yang, K.
    VALUE IN HEALTH, 2024, 27 (12)
  • [38] EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma
    Falchi, Lorenzo
    Morschhauser, Franck
    Linton, Kim
    Huang, Huiqiang
    Galderisi, Faith
    Quadri, Syed
    Zeng, Lingmin
    Hoehn, Daniela
    Seymour, John F.
    BLOOD, 2023, 142
  • [39] Efficacy and safety of Tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 ELARA trial
    Schuster, S.
    Dickinson, M.
    Dreyling, M.
    Martinez-Lopez, J.
    Kolstad, A.
    Butler, J.
    Ghosh, M.
    Popplewell, L.
    Chavez, J.
    Bachy, E.
    Kato, K.
    Harigae, H.
    Kersten, M. J.
    Andreadis, C.
    Riedell, P.
    Zia, A.
    Morisse, M. C.
    Fowler, N. H.
    Thieblemont, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 104 - 105
  • [40] A MATCH-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY (R-CHEMO) FOR RELAPSED AND/OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
    Fox, C.
    Arcaini, L.
    Hernandez-Ilizaliturri, F.
    Tabah, A.
    Parker, C.
    Jones, J.
    Abouzaid, S.
    Watkins, C. L.
    Bachy, E.
    VALUE IN HEALTH, 2019, 22 : S436 - S437
12345